Keywords
DAA
HCV RNA
APRI Score
How to Cite
Abstract
Hepatitis C is a world health problem with a high mortality rate. The Indonesian Ministry of Health has been controlling hepatitis C infection since 2017 using Direct Acting Antiviral (DAA) drugs which have lower side effects and a higher cure rate. This study aims to determine incidence, patient demographic data, and liver fibrosis scores on the successful treatment of hepatitis C infection at RSUD dr. Zainoel Abidin Hospital. Inclusion criteria in this retrospective cohort design was patients with positive anti hepatitis C virus (Anti-HCV). Treatment was carried out when the viral load was detected by giving Sofosbuvir 400 mg per day and Daclatasvir 60 mg per day for 12 weeks, then patient returns to be examined to assess the successful therapy. Thirty eight out of 5002 patients (0.76%) showed positive Anti-HCV, most patients aged over 60 years (39.47%), was dominated by male (55.26%), and most of them are located in Banda Aceh (47 ,36 %). Thirty out of 38 positive anti-HCV patients (78.95%) had HCV RNA, but 15 patients (50%) were not eligible for treatment. Seven out of 15 patients (46.7%) completed DAA treatment. All HCV RNA were undetectable, improved AST values and decreased aspartate aminotransferase-platelet ratio index (APRI) scores which showed improvement in liver fibrosis, after completing therapy. Hepatitis C patients who adhere to treatment and management of hepatitis C will get good results marked by improvement in liver fibrosis and undetectable HCV RNA.
References
Baden, R., Rockstroh, J. K., & Buti, M. (2014), Natural History and Management of Hepatitis C: Does Sex Play a Role?. J Infect Dis, 209(Suppl 3), S81-85. https://doi.org/10.1093/infdis/jiu057.
Chae, H. B., Park, S. M. P., & Youn, S. J. (2013). Direct-acting antiviral for the treatment of chronic hepatitis C: open issues and future perspectives. http://dx.doi.org/10.1155/2013/704912.
Dietz, C., & Maasoumy, B. (2022). Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-from Drug Discovery to Succesfull Implementation in Clinical Practice. Viruses, 14(6), 1325. https://doi.org/10.3390/v14061325.
European Association for the Study of the Liver. (2018). EASL Recommendations on Treatment of Hepatitis C. J Hepatol, 69 (2), 461−511. https://doi.org/10.1016/j.jhep.2018.03.026.
Gani, R. (2014). Hepatitis C. Dalam: Sudoyo, A. W., Setiyohadi, B., Marcellus, A. I. Ed. Buku Ajar Ilmu Penyakit Dalam. Jakarta: Interna Publishing.
Gheorghe, G., Bungau, S., Ceobanu, G., Ilie, M., Bacalbasa, N., Bratu, O. G., dkk. (2021). The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc, 120 (2), 794−803. https://doi.org/10.1016/j.jfma.2020.08.019.
Gupta, E., Bajpai, M., & Choudhary, A. (2014). Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci, 8(1), 19–25. https://doi.org/10.4103/0973-6247.126683.
Humaniora. (2021). Kemenkes Cegah Penularan Dini 18 juta Kasus Hepatitis. https://mediaindonesia.com/humaniora/421503/kemenkes-cegah-penularan-dini-18-juta-kasus-hepatitis.
Kementrian Kesehatan RI. (2019). Surat Keputusan Menteri Kesehatan Republik Indonesia tentang Pedoman Pelayanan Kedokteran Tatalaksana Hepatitis C.
Kementrian Kesehatan RI. (2020). Rencana Aksi Nasional Pengendalian Hepatitis 2020−2024.
Perhimpunan Peneliti Hati Indonesia. (2017). Konsensus Nasional Penetalaksanaan Hepatitus C di Indonesia.
Petersen, J. R., Stevenson, H. L., Khrisna, S. K., Naniwadekar, A., Parkes, J., Cross, R., dkk. (2014). Evaluation of the APRI (AST, platelet ratio index) and ELF™ (Enhanced Liver Fibrosis) tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol, 48(4), 370−376. https://doi.org/10.1097%2FMCG.0b013e3182a87e78.
Schiavon, L.de.L, Narciso-Schiavon, J.L., & de Carvalho-Filho, R.J. (2014). Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol, 20(11), 2854−2866. https://doi.org/10.3748%2Fwjg.v20.i11.2854.
Sebastiani, G., Gkouvatsos, K., & Pantopoulos, K. (2014). Chronic hepatitis C and Liver Fibrosis. World J Gastroenterol, 20 (32), 11033−11053. https://doi.org/10.3748%2Fwjg.v20.i32.11033.
Trivedi, H. D., Lin, S. C., Lau, D. T. Y. (2017). Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterol Hepatol, 13(10), 587–595.
CDC. (2018). Viral Hepatitis Surveillance: United States 2018. https://www.cdc.gov/hepatitis/statistics/2018surveillance/pdfs/2018HepSurveillanceRpt.pdf.
WHO. (2018). Guidelines For the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. https://www.who.int/publications/i/item/9789241550345.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Azzaki, Andrie, Julia